| Literature DB >> 35340763 |
Innocent A Edagha1, Akpan U Ekanem1, Itoro F Usoh2, Victor A Umoh3, Ataben M Ataben1, Anietie A Akpan1.
Abstract
Highly active antiretroviral therapies (HAARTs) are used for the management of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). The present study was designed to characterize the neurotoxicity profile of two popular HAARTs on the brains' antioxidants and hippocampal microanatomical alterations in an in vivo model. Fifteen adults male Wistar rats, were assigned to three groups (n = 5); group I the normal control (NC) received distilled water (5 mL/kg b.wt), groups II administered with oral therapeutic doses of Efavirenz/ Lamivudine/ Tenofovir disproxil fumerate (TLE 17.14 mg/kg b.wt), and group III with Lamivudine/ Nevirapine/ Zidovudine (LNZ 9.28 mg/kg b.wt), respectively which were available for use in University of Uyo Teaching Hospital Nigeria at the time of this experiment. After a 30-day administration, biochemical parameters (catalase, superoxide dismutase, reduced glutathione, glutathione S-transferase, malondialdehyde, glutathione peroxidase, vitamins A, C and E) were determined via serum from blood of ketamine (100 mg/kg, i.p) anesthetized rats. Brains were carefully removed and post-fixed for tissue processing employing hematoxylin and eosin (H&E), cresyl fast violet (CFV) stains, and glial fibrillary acidic protein (GFAP) antibody expression. Results revealed significantly (p < 0.05) decreased antioxidant concentrations and increase in oxidative markers in HAART-administered groups. Normal histoarchitecture was shown in NC, but TLE-administered group demonstrated some neuronal atrophy, and degeneration of pyramidal neurons, with milder distortions in LNZ. TLE-administered group demonstrated intense Nissl substances with chromatolysis compared to LNZ and NC, while GFAP was strongly expressed in TLE-administered group compared to LNZ. In conclusion, TLE is more neurotoxic compared with LNZ.Entities:
Keywords: Highly active antiretroviral therapy; Hippocampus; Neurodegeneration; Oxidative stress
Year: 2022 PMID: 35340763 PMCID: PMC8941179 DOI: 10.1016/j.ibneur.2022.03.004
Source DB: PubMed Journal: IBRO Neurosci Rep ISSN: 2667-2421
Effect of HAARTs on the body and brain weights.
| Group | Initial | Final | Body Weight Change (g) | % Change in | Brain Weight (g) | Organo |
|---|---|---|---|---|---|---|
| NC | 151.20 ± 0.37 | 155.80 ± 1.71 | 4.60 ± 1.34 | + 2.96 | 1.51 ± 0.03 | 0.96 |
| TLE | 173.20 ± 4.19 | 175.80 ± 4.58** | 2.80 ± 0.39 | + 1.47 | 1.52 ± 0.09 | 0.86 |
| LNZ | 167.00 ± 2.85 | 176.00 ± 7.54** | 9.00 ± 4.69 | + 5.20 | 1.55 ± 0.01 | 0.88 |
Data is expressed as Mean ± Standard error of mean (SEM). NC = Normal control; TLE = Efavirenz/ Lamivudine/ Tenofovir disproxil fumarate; LNZ = Lamivudine/Nevaripine/Zidovudine. **Slight increase in body weight.
Effect of HAARTs on the enzymatic brain antioxidants and oxidative stress markers.
| Group | SOD (µmoL/mL/min/mg/pro) | CAT (µmoL/mL/min/mg/pro) | GPx (µmoL/mL/mg/pro) | GST (µmoL/mL/mg/pro) | GSH (µmoL/mL) | MDA (µmoL/mL) |
|---|---|---|---|---|---|---|
| NC | 4.61 ± 0.25 | 58.57 ± 5.50 | 1.42 ± 0.07 | 4.21 ± 0.65 | 20.85 ± 2.28 | 11.29 ± 1.09 |
| TLE | 1.89 ± 0.13a | 18.10 ± 1.28a | 0.58 ± 0.04a | 1.80 ± 0.17a | 24.28 ± 1.14 | 14.37 ± 0.62 |
| LNZ | 3.06 ± 0.19a,b | 36.72 ± 3.44a,b | 0.92 ± 0.05a,b | 3.13 ± 0.20a,b | 25.83 ± 0.88 | 10.33 ± 1.62 |
| F value | 46.95 | 28.17 | 58.46 | 9.06 | 2.68 | 3.19 |
| P value | 0.0001 | 0.0001 | 0.0001 | 0.004 | 0.109 | 0.078 |
Data is expressed as Mean ± Standard error of mean (SEM) and considered significant at (p < 0.05). a = significant compared with NC; b = statistically significant compared with TLE. NC = Normal control; TLE = Efavirenz/ Lamivudine/ Tenofovir disproxil fumarate; LNZ = Lamivudine/ Nevaripine/ Zidovudine.GSH = Reduced glutathione, SOD = Superoxide dismutase, CAT = Catalase, MDA = Malonaldehyde, GPx = Glutathione peroxidase, GST = Glutathione S-transferase.
Effect of HAARTs on the non-enzymatic brain antioxidants.
| Group (n = 5) | Vitamin A (ng/100 g) | Vitamin C (mg/g) | Vitamin E (ng/100 g) |
|---|---|---|---|
| NC | 189.85 ± 40.46 | 6.11 ± 1.47 | 287.88 ± 18.14 |
| TLE | 101.14 ± 12.08 | 3.23 ± 0.64 | 473.11 ± 109.61 |
| LNZ | 144.20 ± 29.42 | 4.63 ± 1.02 | 399.62 ± 68.62 |
| F value | 2.23 | 1.72 | 1.53 |
| P value | 0.150 | 0.220 | 0.256 |
Data is expressed as Mean ± Standard error of mean (SEM) and considered significant at (p < 0.05). NC = Normal control; TLE = Tenofovir disproxil fumarate / Lamivudine/ Efavirenz; LNZ = Lamivudine/ Nevaripine/ Zidovudine.
Fig. 1Photomicrograph showing the effect of HAART (TLE versus LNZ) on the hippocampus (cornu ammonis 1–3). A = atrophy; blue arrow head = hypertrophy; red arrow head = neuronal shrinkage, H&E x400. The LNZ demonstrated neuronal shrinkage compared to the TLE-treated group having pale staining neuropil. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2Photomicrographs showing the effect of HAART (TLE versus LNZ) on hippocampal Nissl substance expression, CFV x400. The LNZ demonstrated mild to moderate Nissl substances compared to the strongly intense expression in the TLE-treated group. Black arrow head = normal Nissl substance; Yellow arrow head = strongly expressed Nissl substance. NC = Normal control. TLE = Tenofovir disproxil fumarate / Lamivudine/Efavirenz LNZ = Lamivudine/ Nevirapine/ Zidovudine. CA1 = cornu ammonis 1, CA2 = cornu ammonis 2, CA3 = cornu ammonis 3. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Photomicrograph of the effect of HAARTs (TLE versus LNZ) on hippocampal expression of GFAP x400. The NC demonstrated mild GFAP expression (black arrow heads) compared to the strong GFAP antibody expression (red arrow heads) in the HAART-administered groups. NC = Normal control. TLE = Tenofovir disproxil fumarate/ Lamivudine/Efavirenz. LNZ = Lamivudine/ Nevirapine/ Zidovudine. CA1 = cornu ammonis 1, CA2 = cornu ammonis 2, CA3 = cornu ammonis 3. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Effect of HAARTs on the hippocampal GFAP expression.
| Group/Region | % of IHC (A) | Intensity of IHC | Final score (A+B) | GFAP Antibody Expression |
|---|---|---|---|---|
| Hippocampal CA1 | ||||
| NC | < 30% (1) | Mild (2) | 3 | Low |
| TLE | > 60% (3) | Strong (3) | 6 | High |
| LNZ | > 60% (3) | Strong (3) | 6 | High |
| Hippocampal CA2 | ||||
| NC | < 30% (1) | Mild (2) | 3 | Low |
| TLE | > 60% (3) | Strong (3) | 6 | High |
| LNZ | > 60% (3) | Strong (3) | 6 | High |
| Hippocampal CA3 | ||||
| NC | < 30% (1) | Mild (2) | 3 | Low |
| TLE | > 60% (3) | Strong (3) | 6 | High |
| LNZ | > 60% (3) | Strong (3) | 6 | High |
NC = Normal control; TLE = Tenofovir disproxil fumarate/ Lamivudine/ Efavirenz; LNZ = Lamivudine/ Nevaripine/ Zidovudine.
Key: % IHC: 0 = 0%; 1 = < 30%; 3 = > 60%
Intensity of IHC: 0 = No reaction; 1 = Weak; 2 = Mild; 3 = Strong
Final Score: Range = 0–6;
0/6 = Negative Reaction
1/6, to 3/6 = Low expression
4/6, to 6/6 = High expression.
| Group | Dosage | Duration (Days) |
|---|---|---|
| NC- Distilled water | (5 mL/kg) | 30 |
| HAART - TLE | 17.14 mg/kg | 30 |
| HAART - LNZ | 9.28 mg/kg | 30 |